Page 13 - Haematologica-April 2018

haematologica Journal of the European Hematology Association
Published by the Ferrata Storti Foundation
e143 Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lodé et al. http://www.haematologica.org/content/103/4/e143
e147 Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo
Mark Kerstjens et al. http://www.haematologica.org/content/103/4/e147
e151 Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort Lisa M. Rimsza, et al.
http://www.haematologica.org/content/103/4/e151
e154 The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model
Marina Wierz et al.
http://www.haematologica.org/content/103/4/e154
e158 No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy
Panagiotis Baliakas et al. http://www.haematologica.org/content/103/4/e158
e162 Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels Pankaj Yadav et al.
http://www.haematologica.org/content/103/4/e162
e165 Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloi- dosis
Richa Manwani et al. http://www.haematologica.org/content/103/4/e165
e169 The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors Hanny Al-Samkari et al.
http://www.haematologica.org/content/103/4/e169
Case Reports
Case reports are available online only at www.haematologica.org/content/103/4.toc
e173 Lethal neonatal bone marrow failure syndrome with multiple congenital abnormalities, including limb defects, due to a constitutional dele- tion of 3’ MECOM
Lars T. van der Veken et al. http://www.haematologica.org/content/103/4/e173
e177 Single-agent dabrafenib for BRAFV600E-mutated histiocytosis Ankush Bhatia et al.
http://www.haematologica.org/content/103/4/e177
e181 Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
Yesim Dargaud et al. http://www.haematologica.org/content/103/4/e181
Haematologica 2018; vol. 103 no. 4 - April 2018 http://www.haematologica.org/